HPV Viral Particle
ALBICIN®, the branded version of a new indication for CANDIN® (Candida albicans skin test antigen for Cellular Hypersensivity) is in Phase 2 clinical studies for evaluation in the treatment of human papilloma virus (HPV) conditions including Verruca vulgaris or common warts. Approximately 20 million people are currently infected in the United States. Of the more than 40 HPV types that infect human mucosal surfaces, certain oncogenic types cause cervical cancer and other less common cancers. Other non-oncogenic HPV types can cause common warts, genital warts, plantar warts, flat warts, and, rarely, respiratory tract warts in children as a condition called juvenile-onset recurrent respiratory papillomatosis (RRP). CANDIN may provide an opportunity to leverage the body’s immune response to more effectively eliminate warts.
This program is investigational, CANDIN is not currently approved for the treatment of common warts.
Leishmania Skin Test Antigen is made from the promastigote form of the parasite Leishmania. Phase 2 studies have been completed. Parasites of the genus Leishmania are found worldwide and cause the diseases of cutaneous or visceral leishmaniasis. The World Health Organization estimates there are 12 million cases of leishmaniasis from a population of 350 million at-risk individuals.
Nielsen BioSciences, Inc. is continuing to leverage its platform of diverse antigenic biologics in the diagnosis and prevention of important human and veterinary diseases. CANDIN® has completed initial clinical veterinary trials for the treatment of canine and equine oral papilloma.
Information on our ongoing clinical trials can be seen at ClinicalTrials.gov.
Use the key word “Nielsen BioSciences.”
© 2017 Nielsen BioSciences, Inc.
The following third-party website was provided for your convenience, and Nielsen BioSciences, Inc. does not endorse, verify, or otherwise support the information contained in these websites. You are subject to the legal terms and conditions of use for third-party websites.